Black Rock Inc. Belite Bio, Inc Transaction History

Black Rock Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$29.5 - $46.02 $53,247 - $83,066	1,805 New	1,805 $82,000
Q2 2023 Aug 11, 2023	SELL	$11.18 - $30.2 $1,017 - $2,748	-91 Reduced 8.61%	966 $13,000
Q1 2023 May 12, 2023	BUY	$25.61 - $33.5 $4,763 - $6,231	186 Added 21.35%	1,057 $31,000
Q4 2022 Feb 13, 2023	BUY	$25.08 - $33.32 $21,844 - $29,021	871 New	871 $26,000

58.3K

Ticker BLTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,867,400
Market Cap $1.13B
Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.